VistaGen Therapeutics Inc

Research VistaGen Therapeutics Inc (VTGN) on Bullrun: market cap USD 30.11M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVTGN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 30.11M
• Financial periodFY2025
• RevenueUSD 486.00K
• Revenue growth-54.3%
• Net income-USD 51.42M

Valuation Snapshot

latest market cap is USD 30.11M.

About VistaGen Therapeutics Inc

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder;

Frequently asked questions

What is VistaGen Therapeutics Inc's market cap?

VistaGen Therapeutics Inc's market capitalization is USD 30.11M.

What does VistaGen Therapeutics Inc do?

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.